These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26018248)

  • 21. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
    Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
    Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcutaneous immunization with pneumococcal surface protein A in mice.
    Nagano H; Kawabata M; Sugita G; Tsuruhara A; Ohori J; Jimura T; Miyashita K; Kurono Y; Tomonaga K; Briles DE; Fujihashi K
    Laryngoscope; 2018 Mar; 128(3):E91-E96. PubMed ID: 29226330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.
    Greene CJ; Marks LR; Hu JC; Reddinger R; Mandell L; Roche-Hakansson H; King-Lyons ND; Connell TD; Hakansson AP
    Infect Immun; 2016 Jun; 84(6):1693-1703. PubMed ID: 27001538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.
    Yu J; Li B; Chen X; Lu J; Wang D; Gu T; Kong W; Wu Y
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29610257
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity of
    Suzuki H; Hosomi K; Nasu A; Kondoh M; Kunisawa J
    Front Immunol; 2018; 9():2320. PubMed ID: 30356722
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
    Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.
    Pimenta FC; Miyaji EN; Arêas AP; Oliveira ML; de Andrade AL; Ho PL; Hollingshead SK; Leite LC
    Infect Immun; 2006 Aug; 74(8):4939-44. PubMed ID: 16861686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).
    Ferreira DM; Oliveira ML; Moreno AT; Ho PL; Briles DE; Miyaji EN
    Microb Pathog; 2010 Jun; 48(6):205-13. PubMed ID: 20206678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal vaccination using claudin-4-targeting.
    Kakutani H; Kondoh M; Fukasaka M; Suzuki H; Hamakubo T; Yagi K
    Biomaterials; 2010 Jul; 31(20):5463-71. PubMed ID: 20398936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.
    Shi H; Wang S; Curtiss R
    Clin Vaccine Immunol; 2013 Jun; 20(6):931-44. PubMed ID: 23616408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.
    Piao Z; Akeda Y; Takeuchi D; Ishii KJ; Ubukata K; Briles DE; Tomono K; Oishi K
    Vaccine; 2014 Sep; 32(43):5607-13. PubMed ID: 25132335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
    Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
    Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice.
    Ezoe H; Akeda Y; Piao Z; Aoshi T; Koyama S; Tanimoto T; Ishii KJ; Oishi K
    Vaccine; 2011 Feb; 29(9):1754-61. PubMed ID: 21219977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.
    Laiño J; Villena J; Suvorov A; Zelaya H; Ortiz Moyano R; Salva S; Alvarez S
    PLoS One; 2018; 13(11):e0206661. PubMed ID: 30395582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
    Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
    J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.